LILLE, France and CAMBRIDGE, Mass., Oct. 25 /PRNewswire/ —
GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical
company at the forefront of drug discovery and development,
focusing on the early diagnosis and preventive treatment of
cardiometabolic and associated disorders, today announced that it
has been selected by Windhover as one of the “Top Biopharma
Projects To Watch” in 2011 in the cardiovascular/metabolic
category. This announcement is part of the conference event
organized by Elsevier Business Intelligence and Windhover
Conferences taking place in Boston from November 2-4, 2010, where
GENFIT will be presenting its latest scientific achievements.
“This year’s list is handpicked in the six hottest
therapeutic areas,” said David Cassak, vice president, content,
for Elsevier Business Intelligence’s publications. “Many of our
past winners have gone on to do big deals, and we expect the same
from this year’s companies.”
The Windhover conference annually elects 10 biopharmaceutical
companies with high-value assets for partnership in six specific
therapeutic areas: cardiovascular/metabolic, oncology,
neuroscience, infectious diseases, inflammatory/autoimmune and a
category including ophthalmology, orphan diseases, and women’s
health.
Dr. Dean W. Hum, chief scientific officer of GENFIT,
added,“Being a well recognized company in the U.S. in our
specific therapeutic area is a great honor for us. We will present
our most advanced drug candidate in the field of diabetes, GFT505,
and our specific and innovative approach to the prevention and
treatment of cardiometabolic diseases. This will be illustrated by
the presentation of other internal research programs, in particular
those dedicated to the discovery of early biomarkers and those
dealing with the connection between circadian cycle dysregulation
and metabolic diseases.”
About Windhover:Windhover Information Inc, an Elsevier
company, has
‘/>”/>
